ASMBS: Metabolic, Bariatric Surgery After GLP-1 Receptor Agonist Use Boosts Weight Loss

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 7, 2026.

via HealthDay

THURSDAY, May 7, 2026 -- Preoperative weight loss with medications does not meaningfully diminish the effectiveness of bariatric surgery, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from May 3 to 7 in San Antonio.

Karan R. Chhabra, M.D., from the NYU Grossman School of Medicine in New York City, and colleagues queried the Epic Cosmos database for adults who filled prescriptions for semaglutide or tirzepatide (glucagon-like peptide-1 receptor agonists [GLP-1 RAs]) within 180 days of bariatric surgery, experienced ≥5 percent total weight loss (TWL) post-GLP-1 RA use, and subsequently underwent Roux-en-Y-gastric bypass (RYGB; 2,395 participants) or sleeve gastrectomy (SG; 4,315 participants) from January 2019 to March 2025. Controls included patients with no prior GLP-1 RA use, but who underwent RYGB (~40,000 individuals) and SG (~87,000 individuals).

The researchers found that mean TWL after RYGB was 25.4, 26.4, and 26.6 percent at one, two, and three years, respectively. Mean TWL after SG was 20.0, 20.1, and 20.5 percent, respectively. Preoperative GLP-1 RA-associated weight loss was just over 8 percent. TWL after RYGB in the non-GLP-1 RA group was 28.2, 29.2, and 28.3 percent, respectively, at one, two, and three years, while TWL after SG was 23.0, 22.6, and 21.8 percent, respectively. By 12 to 36 months after surgery, among patients with diabetes, 45.8 percent in the RYGB group and 61.4 percent in the SG group resumed taking GLP-1 RAs.

"Patients are increasingly having surgery after GLP-1 therapy, making it important to understand how prior medical treatment may influence outcomes," Chhabra said in a statement. "Our findings show that metabolic and bariatric surgery continues to deliver substantial and durable weight loss in this population."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-08 02:39

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords